Alpha 2.0

» Articles » PMID: 26090384

Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease

Overview

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Jun 20

PMID 26090384

Citations 8

Authors

Authors

Chiz-Tzung Chang

Chao-Yuh Yang

Fuu-Jen Tsai

Shih-Yi Lin

Chao-Jung Chen

Affiliations

Affiliations

Soon will be listed here.

Abstract

High-density lipoprotein (HDL) is a lipid and protein complex that consists of apolipoproteins and lower level HDL-associated enzymes. HDL dysfunction is a factor in atherosclerosis and decreases patient survival. Mass spectrometry- (MS-) based proteomics provides a high throughput approach for analyzing the composition and modifications of complex HDL proteins in diseases. HDL can be separated according to size, surface charge, electronegativity, or apoprotein composition. MS-based proteomics on subfractionated HDL then allows investigation of lipoprotein roles in diseases. Herein, we review recent developments in MS-based quantitative proteomic techniques, HDL proteomics and lipoprotein modifications in diseases, and HDL subfractionation studies. We also discuss future directions and perspectives in MS-based proteomics on HDL.

Citing Articles

Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.

Pan B, Chen C, Chen F, Shen M Int J Mol Sci. 2024; 25(23.

PMID: 39684468 PMC: 11641554. DOI: 10.3390/ijms252312759.

Proteomics of high-density lipoprotein subfractions and subclinical atherosclerosis in type 1 diabetes mellitus: a case-control study.

Toyoshima M, Santana M, Silva A, Mello G, Santos-Bezerra D, Goes M Diabetol Metab Syndr. 2023; 15(1):42.

PMID: 36899434 PMC: 10007776. DOI: 10.1186/s13098-023-01007-y.

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention.

Peterson S, Choudhary A, Kalsi A, Zhao S, Alex R, Abraham N Diagnostics (Basel). 2020; 10(11).

PMID: 33233550 PMC: 7699797. DOI: 10.3390/diagnostics10110976.

Urine proteome analysis by C18 plate-matrix-assisted laser desorption/ionization time-of-flight mass spectrometry allows noninvasive differential diagnosis and prediction of diabetic nephropathy.

Chen C, Liao W, Chang C, Liao H, Tsai F PLoS One. 2018; 13(7):e0200945.

PMID: 30024955 PMC: 6053209. DOI: 10.1371/journal.pone.0200945.

Utilizing proteomics to understand and define hypertension: where are we and where do we go?.

Delles C, Carrick E, Graham D, Nicklin S Expert Rev Proteomics. 2018; 15(7):581-592.

PMID: 29999442 PMC: 6092739. DOI: 10.1080/14789450.2018.1493927.

References

1.

Lapolla A, Brioschi M, Banfi C, Tremoli E, Bonfante L, Cristoni S . On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients. J Mass Spectrom. 2007; 43(1):74-81. DOI: 10.1002/jms.1274. View

2.

Lapolla A, Brioschi M, Banfi C, Tremoli E, Cosma C, Bonfante L . Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci. 2007; 1126:295-9. DOI: 10.1196/annals.1433.005. View

3.

Kruger M, Moser M, Ussar S, Thievessen I, Luber C, Forner F . SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008; 134(2):353-64. DOI: 10.1016/j.cell.2008.05.033. View

4.

Briel M, Ferreira-Gonzalez I, You J, Karanicolas P, Akl E, Wu P . Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009; 338:b92. PMC: 2645847. DOI: 10.1136/bmj.b92. View

5.

Mooradian A . Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5(3):150-9. DOI: 10.1038/ncpendmet1066. View

6.

Pahl M, Ni Z, Sepassi L, Moradi H, Vaziri N . Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant. 2009; 24(8):2541-6. PMC: 2727299. DOI: 10.1093/ndt/gfp120. View

7.

Arora S, Husain M, Kumar D, Patni H, Pathak S, Mehrotra D . Human immunodeficiency virus downregulates podocyte apoE expression. Am J Physiol Renal Physiol. 2009; 297(3):F653-61. PMC: 2739717. DOI: 10.1152/ajprenal.90668.2008. View

8.

Arsenault B, Lemieux I, Despres J, Gagnon P, Wareham N, Stroes E . HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis. 2009; 206(1):276-81. DOI: 10.1016/j.atherosclerosis.2009.01.044. View

9.

Cziraky M, Watson K, Talbert R . Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2009; 14(8 Suppl):S3-28. View

10.

Vaziri N . Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial. 2009; 22(6):644-51. PMC: 2874323. DOI: 10.1111/j.1525-139X.2009.00661.x. View

11.

Davidsson P, Hulthe J, Fagerberg B, Camejo G . Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2009; 30(2):156-63. DOI: 10.1161/ATVBAHA.108.179317. View

12.

Madjid M, Ali M, Willerson J . Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J. 2010; 37(1):25-39. PMC: 2829807. View

13.

Bailey D, Ruel I, Hafiane A, Cochrane H, Iatan I, Jauhiainen M . Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J Lipid Res. 2009; 51(4):785-97. PMC: 2842159. DOI: 10.1194/jlr.M001875. View

14.

Terasaka N, Westerterp M, Koetsveld J, Fernandez-Hernando C, Yvan-Charvet L, Wang N . ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol. 2010; 30(11):2219-25. PMC: 4790108. DOI: 10.1161/ATVBAHA.110.213215. View

15.

Khera A, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke M, Jafri K . Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364(2):127-35. PMC: 3030449. DOI: 10.1056/NEJMoa1001689. View

16.

Moore D, McNeal C, Macfarlane R . Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease. Biochem Biophys Res Commun. 2010; 404(4):1034-8. PMC: 3031731. DOI: 10.1016/j.bbrc.2010.12.105. View

17.

Geiger T, Wisniewski J, Cox J, Zanivan S, Kruger M, Ishihama Y . Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat Protoc. 2011; 6(2):147-57. DOI: 10.1038/nprot.2010.192. View

18.

Rosenson R, Brewer Jr H, Chapman M, Fazio S, Hussain M, Kontush A . HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57(3):392-410. DOI: 10.1373/clinchem.2010.155333. View

19.

Brodde M, Korporaal S, Herminghaus G, Fobker M, Van Berkel T, Tietge U . Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids. Atherosclerosis. 2011; 215(2):374-82. DOI: 10.1016/j.atherosclerosis.2010.12.026. View

20.

Cacciagiu L, Gonzalez A, Gomez Rosso L, Merono T, De Marziani G, Elbert A . HDL-associated enzymes and proteins in hemodialysis patients. Clin Biochem. 2011; 45(3):243-8. DOI: 10.1016/j.clinbiochem.2011.12.008. View